Mova will market a combination treatment for urinary tract infection under an agreement announced Aug. 11. Zotrim combines two commonly prescribed drugs in "compliance packaging." Dynagen will manufacture the product for Mova through its subsidiary, Able Labs. Mova will provide funds for completion of the Zotrim NDA, to be filed in the fourth quarter of 1998. Dynagen estimates the agreement's value at $1 mil. in the first year and $1.5 mil. per year thereafter
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth